panitumumab
amgen,takeda
['paradigm']
#asco22 #plenary the results of the paradigm trial was somewhat expected and was consistent with fire-3 trial lack of improvement in pfs but improvement in os perhaps driven by clonal selection process 
Medical Oncologist @MoffittNews Asst. Prof @USFNews | Alumnus @WinshipAtEmory |Research in Colorectal Cancer| lead guitar| tweets=my own